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Shortened REM Latency PostECT Is Associated with 
Rapid Recurrence of Depressive Symptomatology 
Leon Grunhaus, James E. Shipley, Alan Eiser, Atul C. Pande, Rajiv Tandon, 
Anna Remen, and John F. Greden 
I 
Electroconvulsive therapy ( ECT) is highly effective in the treatment o f  major depressive disorder 
(MDD). The l-year relapse rates are reported to be high and in the 30%-60% range, however. 
To test whether polysomnography (PS) can identify patients with a propensity for  relapse we 
studied 20 patients, responders to a course o f  ECT, with PS studies. All patients met baseline 
diagnostic criteria for MDD, were treated with ECT following standardized protocols, had PS 
studies performed after the course of ECT in a medication-free state, received maintenance 
antidepressants postECT, and were foltowed periodically with phone interviews. The recurrence 
of  depressive symptoms was determined at 3 months and 6 months after discharge. Fifty-five 
percent of  the patients were symptomatic when evaluated 6 months after the ECT. Sleep Onset 
rapid eye movement (REM) periods were identified in 55% of  the patients. As a group, patients 
who had experienced a recurrence of  depressive symptoms by 6 months after discharge, had 
significantly shorter REM latencies after the course of  ECT. A shorter REM latency after ECT 
identified patients who at six months demonstrated significant depressive symptomatology. 
Shortened REM latency after ECT in patients with MDD appears to be a correlate of  vulnerabil- 
ity for relapse. 
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Introduction 
Preventing repeat episodes of Major Depressive Disorder 
(MDD) is one of the most relevant topics in clinical psychi- 
atry today Recent studies suggest that a significant propor- 
tion of patients with MDD suffer from recurrent episodes, 
residual symptomatology, or commit suicide (Kiloh et al 
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1988; Wells et al 1989). The masons for this malignant 
course are far from being understood. Insufficient use of 
antidepressant treatment (Keller et al 1992) or their use for 
inadequate lengths of time most certainly plays a prominent 
role in this poor prognosis (Kupfer et a11992; Kupfer 1992). 
Factors related to the pathogenesis of the disorder are prob- 
ably of major relevance to this complicated prognosis, how- 
ever. 
A similar procwated course of illness has been described 
for patients with MDD treated with electroconvuisive ther- 
apy (ECT). Despite very high rates of response during the 
acute episode of illness, as high as 70%-90% (APA 1990; 
Abrams 1992), the 1-to-2-year relapse rates following ECT 
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may be in the range of 50% (Spiker et al 1985; Amnson et al 
1987; Abou-Saleh and Coppan 1988; Sackeim et al 1990; 
Winokur et al 1990; Sackeim et al 1993). This seems to be 
particularly true if the MDD has been treatment resistant or 
delusional in nature. These high relapse rates are not just a 
consequence of  insufficient treatment and appear related to 
the pathogenesis of  the disorder. 
It is self-evident that the identification of  specific factors, 
which may play a role in the outcome of  mood disorders is of  
particular importance in MDD, and in MDD treated with 
ECT in particular. Such factors could be studied with regard 
to diagnosis, severity of illness, response to treatment, and 
longitudinal course. Polysonmography (PS) has been ex- 
tensively studied in MDD and more recently also in MDD 
patients treated with ECT (Gmnhans et a11985, 1988; Hoff- 
mann et al 1985: Coffey et al 1988; Grunhaus et al unpub- 
lished data). Although there are questions regarding the 
specificity of the PS findings in MDD, patients with MDD 
and particularly patients referred for ECT, demonstrate PS 
abnormalities most often (Benca ct ai 1992) (Gmnhaus et al 
unpublished data). From the various PS abnormalities de- 
scribed, very short rapid eye movement (REM) latency 
appears to be most characteristic of severe depressives 
(Reynolds et al 1982, 1985, 1991; Thase et al 1986). Sleep 
onset REM periods (SOREM), a particularly severe form of 
shortened REM latency, was described in 17 of 25 patients 
referred for ECT (Gmnhaus et al submitted). Interestingly, 
10 of these patients continued to demonstrate SOREM after 
the course of ECT. 
Shortened REM latency during baseline PS recordings in 
patients with MDD appears to be of prognostic significance. 
Giles et al (1987) and Reynolds et al (1989) have reported 
that in MDD patients treated successfully with antidepres- 
sant medications, reduced REM latency in baseline studies 
was associated with increased incidence of recurrence. To 
test whether shortened REM latency in patients treated with 
ECT is associated with early recurrence of depressive 
symptomatology, we followed 20 patients who had been 
successfully treated with ECT and who had PS studies 
recorded postECT. 
It is more comInon to perform. PS studies before active 
treatment is started. Seriously ill patients have great diffi- 
culty remaining medication-free for the period necessary to 
perform sleep studies, however. Performing PS while on 
psychotropic medications would not have been productive 
due to the major effects these medications have on PS 
(Kupfer et ai 1989, 1991; Reynolds et al 1989). We there- 
fore use the period of administration of ECT to both im- 
prove the clinical condition of the patients and to withdraw 
all psychotropic medications for at least 10 days before the 
PS. This methodological change permitted both the inclu- 
sion of larger numbers of patients and exploring the rela- 
tionship of postECT PS findings with clinical outcome. 
Patients with recurring depressive symptomatology dem- 
onstrated shortened REM latency postECT significantly 
more often than patients remaining well. 
Methods and Materials 
To be included in this study patients were required to have a 
baseline 17-item Hamilton Rating Scale for Depression 
(HRSD) score (Hamilton 1960) ~> I8, to have responded to 
the course of ECT, and to have had PS studies performed 
POstECT. Patients were considered to be responders to ECT 
if they maintained an HRSD score ~ 10 and a Global 
Assessment Scale (GAS) >~ 70 for at least I week after the 
course of ECT. 
Twenty consecutive patients (6 men and 14 women) re- 
sponders to a course of ECT and who met our inclusion 
criteria pa~cipated in this study. All subjects were inpa- 
tients of the Psychiatry Department of the University of 
Michigan Hospital. The baseline clinical evaluation in- 
cluded several interviews with senior clinicians, a compre- 
hensive physical and laboratory work-up, interviews with 
family members whenever available, and a consensus diag- 
nosis whereby at least two clinicians met to ascertain the 
presence of the Research Diagnostic Criteria (RDC) 
(Spitzer et al 1978) for MDD. All patients met diagnostic 
criteria for MDD, 12 of them were endogenous, 11 of them 
were psychotic, and three were bipolar. No patient who had 
been treated with ECT in the previous 6 months was in- 
cluded in the study. 
Patients were rated weekly with the 17-item HRSD. 
HRSDs were collected by trained staff supervised by the 
senior investigator in this project (LG). To define response 
we used HRSD scores obtained within I week of the offset 
of the ECT course. The mean HRSD score preECT was 26.7 
+ 5.3 with a range of 19 to 39, whereas mean postECT 
HRSD score was 3.8 + 2.3 with a range of 0 to 8. The mean 
number of previous episodes was 2.8 +- 2.3, and the mean 
age of the first episode of MDD was 52.2 -+ 17.7. Age 
ranged from 37 to 85 years with a mean of 62.3 ± 13.6. 
Demographic and descriptive variables are presented in 
Table 1. 
ECT Procedure 
ECT was performed according to the guidelines of the 
American Psychiatric Association (1978, 1990). Referral 
for ECT was made by the attending physician based on 
clinical criteria. All patients received an extensive preECT 
workup that included a complete physical and laboratory 
examination, chest x-rays, electrocardiogram, and consul- 
rations with an anesthesiologist for all patients, and a car- 
diologist for those patients with preexisting cardiac pathol- 
ogy or who were over the age of 50. Patients incIuded in this 
study were all American Society for Anesthesia risk I, II, or 
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Table 1. Demographic andClinicai Variables 
HRSD 
Age of Number of Post ECT Relapse at 
Pa~'nt Diagnosis" Gender Age onset episodes Psychosis R E M ~ y b  PmECT PestEC'r 6menths • 
I MDD-ED M 69 67 1 yes I 27 8 yes 
2 MDD-ED F 80 40 4 yes I0 19 I yes 
3 MDD-ED F 54 54 I yes 83.5 39 6 no 
4 MDD F 73 67 3 no 16.5 25 5 yes 
5 MDD-ED F 37 20 4 no 41.5 27 2 no 
6 MDD F 41 10 6 no i !.5 21 3 yes 
7 MDD-ED F 69 - -  - -  yes 0 26 5 no 
8 MDD-ED F 51 29 10 yes 0 30 6 yes 
9 MDD-ED F 53 51 2 no 96 26 l no 
I0 MDD-ED M 75 65 I yes 150 30 1 no 
I I MDD-ED F 64 49 7 no 25 28 6 yes 
12 MDD-ED F 72 72 1 yes 5 31 2 no 
13 MDD-ED F 53 39 4 no 67 18 4 yes 
14 MDD-ED F 70 56 3 no 67 26 7 no 
15 MDD-ED M 68 66 ! yes 6.5 37 3 no 
16 MDD-ED M 67 66 i yes 8 28 4 yes 
17 MDD-ED M 61 61 ! yes 0 21 5 yes 
18 MDD F 37 36 I no 55 22 $ yes 
19 MDD.ED F 85 64 3 yes 169 29 ! no 
20 MDD-ED M 66 63 3 no 0 25 0 yes 
Means±SD: F: 14~!:6 62.3__. 13.6 52.2--. 17.7 2.8-+2.3 Y: l l /N:9 40.6-+50.9 26.7±5.3 3.8__2.3 Y: II/N:9 
MDD = major depressive disorder, El) -- endogenous, HRSD = Hamiltm Rating Scale for Depression, ! 7-item. 
"RDCdiagno~is, 
"REM latency recorded in minutes, 
¢"Relapse" defined by a Global Assessment Scale ~ore < 55. 
III. All patients signed a wri~en consent for ECT. A stan- 
dardized method for obtaining consent including the view- 
ing of an educational videotape on ECT (Gmnhaus and 
Barroso-Wahl 1988), the reading of a booklet on ECT 
(Gmnhaus and Barroso-Wahl 1989) and discussions about 
ECT with a dedicated ECT nurse and the treating psychia- 
trist was used. ECT was performed between 8 and 10 AM in 
a specialized ECT suite. All patients were observed in the 
recovery area until judged sufficiently awake for transport 
to t~ir  'unit. A ~ l i n e r g i c  medications were not pre- 
scribed preECT. The administration of anticholinergic 
rm cations, especially in elderly patients, is associated 
with higher baseline pulse and higher peak pulses during 
ECT. Thus, the potential negative effects in populations at 
risk outweigh the potential benefits (Bouckoms et al 1989). 
Although we used a modified seizure threshold titration 
method (Sackeim et al 1987) and occasionally administered 
subconvuisive electrical stimulus, no untoward cardiovas- 
cular effects were observed. The only medications allowed 
during the ECT course were cardiac or antireflux medica- 
tions. Methohexital (0.75 mg/kg), succinylcholine (1 
mg/kg), and constant 100% oxygen through a face mask 
were administered in all treatments. Short acting beta- 
blocking agents (labetalol and esmolol) were used as neces- 
sary for cardiovascular stabilization. Midazolam, a short 
acting benzodiazepine, was used occasionally for signifi- 
cant postECT agitation; in all cases the last dose of  midazo- 
lain was administered at least 10 days before the postECT 
SP. The equipment used for the administration of the ECT 
included a Mecta SRI and SR2 machines which deriver a 
bidirectional quadratic brief-pulse stimulus. The choice of 
electrode placement and the switch from unilateral to bilat- 
eral placement was not controlled for the purposes of this 
study and was left for the clinician administering ECT to 
decide. Eight patients received unilateral ECTs and 12 pa- 
tients received bilateral ECT. Electrical parameters were 
determined using a modified seizure threshold titration 
method (Sackeim et al 1987). Seizure threshold was deter- 
mined during the first ECT treatment. For the following 
treatment, energy parameters were set to deliver 150% of 
the initial charge. During the remainder of the ECT course, 
energy parameters were increased by one or two settings 
every third or fourth treatment. Length of seizure was moni- 
toned by two clinicians with the cuff-method and restimula- 
tion at higher energy parameters was performed if the sei- 
zure lasted <25 sec. The mean seizure duration (arrived at 
by dividing the total seizure seconds by the number of 
treatments) was 39.2 -+ 12.9 sec. The length of  the ECT 
treatment was not standardized and the ECT course was 
terminated after the attending physician treating the patient 
considered improvement sufficient or that no further bene- 
fits from ECT could be expected. The mean number of 
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ECT's was 7.7 ± 2.5. 
PS Procedures 
All patients were on psychotmpic medication preECT. 
Within days of starting the ECT course medications were 
tapered, however. Patients had been free of psychou'opic 
medication, with the exception of the short-acting bmbitu- 
rates and muscle relaxants administered during ECT, for at 
least 10 days before the postECT PS studies. PS studies 
were performed no sooner than 24 hr and no later than 96 hr 
from the last ECT. Performing PS studies postECT permit- 
ted the inclusion of patients whose severity of illness at 
baseline was such that a medication-free observation period 
was unattainable. This methodological change allows per- 
forming studies over shorter periods of time. As an example, 
for our previous study of PS studies preECT and postECT 
(Grunhaus et al unpublished data) it took over 5 years to 
collect a sample of 25 patients. The sample we are currently 
reporting on, postECT PS studies on ECT responders, was 
collected over a period of 14 months. 
Daytime naps during the PS studies days were not per- 
mitted. PS tracings were recorded and scored by technicians 
blind to the fact that patients were receiving ECT. Clinicians 
performing clinical ratings were kept blind to PS results. 
Patients were recorded from their hospital beds, all of which 
were directly wired to the sleep laboratory control room. 
Recordings were done using a Telefactor (West Consho- 
hocken, PA) encoder-decoder system and recorded on a 
Grass model 78 polygraph, with a resulting nominal EEG 
band pass of 0.3-30 Hz. For all subjects eleclrode imped- 
ance's were less than 5,000 ohms and paper speed was 
10 mm/sec. 
On the first night of study a full montage polysomnogram 
was used to rule out primary sleep disorders such as sleep 
apnea or nocturnal myoclonus. This i~eluded electroence- 
phalogram (EEG) (C3/A2), referential electrooculogram 
(EOG), submental elecWomyo~;,--am (EMG), resph-ato~ 
monitoring (nasal-oral the,,'mistors, abdominal and chest 
strain gauges, and ear oximetry), electrocardiogram, and 
EMG of the anterior tibialis muscle. On the subsequent 
night, information required for sleep staging was recorded 
(EEG, EOG, and chin EMG). Patients having primary sleep 
disorders were excluded from the study and no additional 
information was recorded. 
All polygraph records were scored visually using a 60- 
sec epoch according to modified Rechtshaffen and Kale's 
criteria (Rechtschaffenet al 1968). The visually scored EEG 
sleep variables were divided into three groups: sleep conti- 
nuity, sleep architecture, and REM sleep indices. (1) sleep 
continuity indices: total recording period (TRP); time spent 
asleep (TSA) = net sleep time; sleep efficiency (TSA/TRP x 
100); sleep latency (time from the beginning of the record- 
ing until the onset of stage 2 sleep for at least 10 min 
interrupted by no raore llum 2 rain of stage 1, or one minute 
of stage 1 plus one minute of wakefulness); sleep ~ -  
nance (percentage of time asleep during the total recording 
period after sleep latency), wakefulness after ~ onset 
(time spent awake during the night which is ~ by 
sleep); and wakefulness during the last 2 hr of the reconling. 
(2) Sleep architectme indices: percentages of net sleep ~ 
spent in stages 1,2, 3, 4, anddelta~ and REM. (3) ~ ~ p  
indices: REM time (RT); REM activity (RA, an integrative 
measure of the frequency of rapid eye nmvernents scored by 
visual inspection on a scale of O.-S per rain o f ~  sleep); 
REM density ~.A/RT); REM sleep latency (the time be- 
tween sleep onset and the first REM period). A REM 
was defined as a minimum of 3 min Of REM sleep w ~ n  30 
rain of each other. Patients were considered as having a 
sleep onset REM period (SOREM) period when the average 
of both nights of REM latency was less than 20 rain. 
FoUow-Up Period 
Maintenance pharmacotherapy was initiated in all cases 
following the last night of  PS recording. Antidepressant 
regimen was chosen by the clinician in charge of the case. 
The antidepressants prescribed included: fluoxetine, nor- 
triptyline, and desipramine. Patients were discharged with 
the recommendation to achieve a therapeutic dose within I 
week of discharge. At 3 and 6 months after discharge pa- 
tients were contacted by one of the investigators. The fol- 
low-up protocol was approved by the institutional review 
board and patients consented to the phone interview. This 
phone interview lasted approximately 30 min and included 
questions concerning clinical outcome, medication regi- 
men, and compliance. The pharmacological treatment was 
assessed with the Michigan Adequacy of Treatment Scale 
(MATS) (Gmnhaus and Remen 1993). This scale rates the 
adequacy of antidepressant treatment on a one-to-five 
score, one being insufficient treatment and five being the 
highest level of treatment recommended for a particular 
antidepressant medication (i.e., fluoxetine 80 rag/day). All 
patients were required to have at least a level two for inclu- 
sion in the study. Level two represents 50-75 mg a day of 
nortriptyline, 20-39 mga day of fluoxetine, or 100-150 mg 
a day of desipramine. 
The clinical condition was assessed with a standardized 
set of questions aimed at obtaining a GAS score. We chose 
to evaluate patients with the GAS to assess not just signs of 
relapse but also dysfunctional states which have been re- 
ported as being quite common in MDD patients (Wells et al 
1989). We classified patients into thor ~ remairing well 
(GAS >~ 70), those having residual symptoma[ology (GAS 
in the range of 50--69) and not meeting ~ criteria for 
MDD, and those having had a recurrence or relapse (GAS < 
50) and meeting ~ criteria for MDD. 
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Deta Analysis 
Logarithmic transformation was performed on those vari- 
ables with significant skewness and kurtosis. Patients were 
grouped into two categories based on the GAS scores; the 
``remaining well" group were those with a GAS >~ 70 and 
the "symptomatic" group were those who demonstrated 
recurrence of depressive and dysfunctional symptoms 
(GAS --- 69). Patients in the "residual" and "relapse" 
groups were compared on a number of core variables, like 
REM latency and presence of SOREM, and found not to be 
different. Therefore, these groups were collapsed into one 
category, the "sympto_m..~c" category, for data analysis. 
Comparisons were based on the results from the 6-month 
follow-up interview. 
Analyses included t-tests for continuous data, and X 2 for 
categorical data. Results from the two nights of sleep 
recordings were averaged for data analysis. To test whether 
certain clinical or PS variables were associated with the 
recurrence of symptoms, we performed several logistic re- 
gressions where the independent variable was the parameter 
of interest and the dependent variable the group outcome. 
The relatively small sample size did not allow including the 
variables in one analysis, therefore we performed separate 
analysis for age, age of onset, number of episodes, REM 
latency, REM density, EMA. and %SE. Statistical analysis 
was performed on a Macintosh SE/30 computer using the 
Statview II statistical package (Statview 1985) and the JMP 
program (SAS Institute Inc 1989). 
Results 
Only nine patients (45%) remained well 6 months after the 
ECT course. Seven (35%) of the remaining 11 patients had 
relapsed, and 4 (20%) demonstrated significant depressive 
symptoms but did not meet full diagnostic criteria for MDD. 
As mentioned previously the latter two categories were 
grouped together for data analysis. 
We compared "remaining well" patients with "sympto- 
matic" patients on a number of clinical variables; these 
included: age of onset, preECT and postECT HRSD score, 
number of ECr's, mean seizure duration (total seizure time 
d by the number of treatments), presence of psychosis, and 
level of MATS treatment preECT and during follow-up. Of 
these, only the preECT HRSD was significantly different 
between the groups with patients in the "symptomatic" 
category having lower preECT scores than patients in the 
"remaining well" category (24 _+ 4.0 versus 30.1 + 
4.9, t = 3.1, p = --<0.01). No age difference was identified 
between the "remaining well" and "symptomatic" categn- 
ries (60.2_ 13.3 versus 64.8_ 14.4,NS). 
The PS parameters of sleep continuity, sleep architecture, 
and REM were also analyzed for the 6-month time point. 
REM latency was the only variable differentiating between 
the groups, with patients in the "symptomatic" category 
demonstrating significantly shorter REM latencies (17.6 ± 
23 versus 68.7 ± 62.3, t = 2.5. p = 0.02).  Eleven (55%) 
patients had SOREM after the treatment. (See Figure 1). 
The logistic regression demonstrated that shorter REM 
latency occurs significantly more often in symptomatic pa- 
tients (analysis of  logLikelihood, C total 13.8, X 2 = 6.1, p ffi 
0.01). The regression line demonstrated that a REM latency 
of -< 20 rain was associated with a 67% chance of being 
symptomatic by 6 months after the ECT course. (See 
Figure 2). 
Discussion 
This study was designed to test whether sleep variables, and 
particularly shortened REM latency, have value in the pre- 
diction of relapse of depressive symptomatology. Patients 
included in this study had to meet three requirements: to 
have responded to the course of ECT, to hav e had PS studies 
performed after ECT, and to have remained in follow-up 
taking adequate maintenance phannacotherapy for 6 
months after the ECT's. REM latency was the one sleep 
variable that differentiated between symptomatic and re- 
maining well patients. Shortened REM latency postECT 
was associated with the recurrence of depressive symptom- 
atology, as demonstrated both by mean group values and by 
logistic regression. As a group, patients who were sympto- 
matic at follnw-up had significantly shorter REM latency 
postECT than patients remaining well (/7 = 0.02). A short- 
ened REM latency postECT identified patients who later 
became symptomatic (p = 0.01). This was especially tree for 
REM latencies -< 20 mix (SOREM). The regression curve 
suggests that patients with SOREM postECT had close to a 
70% chance of being symptomatic 6 months after ECT. 
Shortened REM latency was evident and equally low, both 
in patients who had fully relapsed and in those who demon- 
stra~t,~l_ significant s~ .umptomatology but did not meet criteria 
for a full depressive relapse. These findings suggest that 
shortened REM latency postECT (and particularly the pres- 
ence of SOREM periods), is a vulnerability factor in MDD 
and predictive of an ominous course of illness. 
Further support for the proposal that shortened REM 
latency is a vulnerability factor in MDD and is frequently 
associated with relapse, comes from the reports by Giles et 
al (1987) and Reynolds et al (1989). Giles et al followed 25 
patients with MDD who responded to antidepressant treat- 
ment either in the form of medication or cognitive therapy. 
The authors found that during the follow-up period those 
patients who had shorter REM latency (-<65 min) during 
baseline studies, relapsed more frequently and sooner than 
patients with longer REM latencies (>65 rain). By the 
12-month of follow-up, the cumulative likelihood of recur- 
rence in the group with longer latency was 20%, whereas in 




1 6 0 _  
140 











Q O  • 
• • 











0 .6 -  







3 months 6 months 
p=.06 I1=.02 
J 
l l | J d i l l 




Figure 2. Results of the logistic regression analysis exploring the 
value of shorter REM latencies in predicting the "remaining well" 
and "symptomatic" groups. Due to limitations of the computer 
program categories were renamed "good" and poor." The results 
of the analysis of loglikelihood (X 2 = 6.09, p = 0.01) suggest that 
shorter REM latencies are associated with a greater propensity for 




Figure I. REM latency postECT 
according to the "sv~:7omatic" 
and "remaining well" categories. 
Results are ptesent~ for both the 3 
and 6 months follow-up observa- 
tions. 
the group with shorter latency the likel~c.,c,d was approxi- 
mately 65%. These authors concluded that REM latency 
could represent both a trait marker and a vulnerability factor 
in MDD. Reynolds et al reported on 27 geriatric patients 
with MDD treated with nortriptyline. The four patients that 
relapsed during the follow-up, all had had shorter REM 
latency at basefine (mean pretreatment REM latepcy of 
18.4 + 7.4). 
Short REM latency in MDD has been traditionally 
viewed as a state marker of acuity, one that should revert to 
normal with recovery. More recent studies, including ours, 
have found shortened REM latency persisting even after 
several months of  recovery (Hauri et al 1974; Puig-Antich et 
al 1983; Giles et al 1987). The pathogenic relevance of 
shortened REM latency is therefore unclear. Is it a state 
marker of MDD? Is it a consequence of depression that 
remits more slowly? Is it an indicator of continued vulnera- 
bility? and/or is it a potential predictor of depression for 
people who are unaffected but at risk? (Reynolds et al 
1987). The studies by Giles et aL Reynolds et aI, and ours 
provide strong support for the hy~-~othesis that shortened 
REM latency in MDD is an indicator ¢f continued vulnera- 
bility. 
Other sleep abnormalities persisting well into the recov- 
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ery periods have been de~ribed (Hauri et al 1974; Puig- 
Antich et al 1983; Rush et al 1986). Only a computerized 
measure of delta waves has been reported to predict relapse 
in patients with MDD Kupfer et a11990), however. Patients 
with a reduced delta count ratio between the first and second 
REM periods were found to relapse more rapidly (during a 
phase with no medication) than patients with high delta 
ratios. In our study no other sleep variable was found to 
differentiate between the groups. The measurement of delta 
counts, which requires computerized readings oftbe SP was 
not performed. 
Of interest is the fact that in the studies of Giles et al 
(1987) and Kupfer et al (1990), patients were maintained on 
medications for a standardized period of time, and it was 
only after withdrawal of the medications that relapse oc- 
curred. In our study, recurrence of symptoms occurred 
much sooner and while patients were receiving antidepres- 
sant treatment. Patients in our study reportedly had a very 
high proportion of SOREM periods. It is possible then, that 
shorter REM latencies and particularly SOREM periods 
reflect a more profound neurobiological abnormality, one 
that is reflected both in clinical severity and in rapid relapse. 
The high incidence of SOREM periods in ECT-treated 
patients is quite remarkable. In this sample, 55% of the 
patients demonstrated SOREM postECT. In a previous 
study from our group we found preECT SOREM periods in 
over 70% of the MDD patients (Gmnhaus et al unpublished 
data). Thase et al and Kupfer et al (1986; Thase et al 1986) 
have reported that some 50% of patients with delusional 
MDD have SOREM periods. In our sample approximately 
half of the patients were delusional and most of them had 
SOREM (see Table 1). Very short REM latencies may 
reflect neurophysiological and neurochemical imbalances 
associated with this form of severe depressi._~n. Post (Post et 
al 1986; Post 1992a, 1992b) has recently advanced a com- 
prebensive hypothesis exploring the interactions between 
environmental events, m~lecular biology changes and a f- 
fective illness. According to this hypothesis, recurrent epi- 
sodes, and possibly severe, protracted or refractory episodes 
of affective illness, impact gene expression in such a way 
that changes t.aduced by the illness are incorporated, possi- 
bly as "memory" traces, and have the potential for mediat- 
ing vulnerab~,l:~y to recurrence in a long-lasting fashion. The 
persistence of these neurobiological alterations after recov- 
ery of the clinical syndrome may be associated with a vul- 
nerability for relapse (Post 1992). To hypothesize that the 
neurobiological changes proposed by Post are the forerun- 
hers of SOREM and relapse in our patients would be highly 
speculative at t.his point. Consideration of this possibility 
reinforces the need for long-term prophylaxis in these pa- 
tients, however. 
Some comments concerning our methods are needed: 
(1) Regarding the sample ~;ze. This report is based on a 
small sample size, thus the conclusions need to be consid- 
ered preliminaw. This report was written to encourage au- 
thors treating this very sick population to address the issue 
of sleep and recovery after treatment with ECT. (2) On the 
timing of the PS studies, as mentioned, performing SP stud- 
ies only after the course of ECT is less common. We decided 
on this approach for the following two reasons. First, it 
allowed us to include a more representative sample of ECT- 
treated patients. Patients referred for ECT are usually quite 
ill and cannot tolerate the drug-free period required for PS 
studies, therefore they are seldomly included in baseline PS 
studies; collecting a representative sample is, therefore, a 
lengthy process. And ~.econd, it is possible that biological 
findings obtained posttreatment more accurately reflect the 
vulnerability for relapse than baseline studies. (3) Regard- 
ing post-ECT clinical care, follow-up was left to clinicians 
in the community who received extensive recommenda- 
tions from the research team. Although these were sophisti- 
cated clinicians who followed our recommendations very 
carefully, a closer follow-up by the research team would 
have provided more accurate information regarding the 
time to relapse, compliance with treatment, and issues of 
dosage and type of antidepressant medication. (4) Regard- 
ing the effects of age on the results, the effects of  age on PS 
parameters are known to be significant. In the preliminary 
analysis we performed on this sample, age was not a factor 
on either clinical outcome at 6 months or REM latency, 
however. Whether age is less relevant for either PS studies 
after the recovery from the acute episode or for longitudinal 
outcome, is a question worthwhile exploring in larger sam- 
ple. (5) On the effects of ECT on PS parameters, ECT may 
impact on PS parameters through its antidepressant actions 
and through other nonspecific neurochemical actions. 
These nonspecific effects may affect REM parameters in 
such a way that interpretation of PS results becomes diffi- 
cult. For example, experiments performed in cats in the late 
!960s~ demons~ted ~at  elec~cal con~-elsions exert 
marked effects on REM sleep parameters (Cohen and De- 
ment 1966~ Kaelbling et al 1968) and lead to reductions in 
REM time, REM activity, and number of REM periods. 
Although we cannot separate these two effects of  ECT, the 
presence of shortened REM latency preECT in a high pro- 
portion of patients (Gmnhaus et al unpublished data), sug- 
gests that our finding ofpostECT shortened REM latency is 
related to the underlying diathesis and not to the effects of 
ECf. 
The potential application of the findings we have re- 
ported to the study of the pathophysiology of severe depres- 
sion and for treatment planing in this disorder, could be 
extensive. For example, determining whether SOREM peri- 
ods can be modified by an anticholinergic challenge could 
be used to test the "cholinergic overdrive hypothesis" 
(Berger et al 1989) of shortened REM latency in MDD. 
Short REM L a ~ y  and Outcome PostECT atoL I~¥CtlIATItY 22 t 
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Clinically, determining whether patients with shortened 
REM latency postECT have specific treatment require- 
ments could be instrumental in improving the outcome of 
this group of patients. It is possible that patients with short- 
ened REM latency require maintenance strategies that may 
include maintenance ECT or more than one psychotmpic 
agent. 
It is evident that additional studies are required before 
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